Cochrane · systematic review · CD009524
Latrepirdine for Alzheimer's disease
Chau, S, Herrmann, N, Ruthirakuhan, MT, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
Dementia and Cognitive ImprovementAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
9
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 1 · 10%Very low 0 · 0%Low 4 · 40%Moderate 4 · 40%High 1 · 10%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings for efficacy measures
Population: patients with Alzheimer's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
CIBIC‐Plus (change from baseline at 26 weeks) Scale: 1 to 7 (1 = very much improved, 4 = no change, 7 = very much worse) | no estimate extracted | 1 study · 183 participants | Low |
ADAS‐Cog Scale from: 1 to 70 (higher scores represent worse performance) | no estimate extracted | 3 studies · 1243 participants | Low |
MMSE Scale from: 0 to 30 (higher scores represent better performance) | no estimate extracted | 3 studies · 1243 participants | Low |
ADCS‐ADL Scale from: 0 to 54 (higher scores represent better performance) | no estimate extracted | 3 studies · 1243 participants | Low |
NPI Scale from: 0 to 144 (higher scores represent worse performance) | no estimate extracted | 3 studies · 1243 participants | High |
Summary of findings for safety and tolerability
Population: patients with Alzheimer's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Adverse events | RR 1.03 [0.93, 1.14] | 4 studies · 1034 participants | Moderate |
Serious adverse events | RR 0.86 [0.55, 1.35] | 4 studies · 1034 participants | Moderate |
Total dropouts | RR 0.91 [0.65, 1.27] | 4 studies · 1034 participants | Moderate |
Dropouts due to adverse events | RR 0.98 [0.57, 1.67] | 3 studies · 1010 participants | Moderate |
publication bias | no estimate extracted | 1 participants | Ungraded |